Visvin 30 mg contains decitabine, a chemotherapy medicine used to treat certain blood and bone marrow cancers. It belongs to a class of drugs called hypomethylating agents and is especially helpful in conditions where the bone marrow does not produce healthy blood cells. Visvin is typically given under the supervision of a specialist in a hospital or clinic setting. Its use has become a valuable option for patients with difficult-to-treat blood disorders.

Mechanism of Action

Decitabine works at the DNA level. In some cancers, specific genes that should help control cell growth are switched off due to abnormal DNA methylation. Decitabine helps by reducing this methylation, thereby reactivating these important genes. This allows the cancerous cells to stop growing and may even lead them to die in a controlled way. Over time, it also supports the bone marrow in making healthier blood cells.

Uses

Visvin is mainly used in the treatment of:

• Myelodysplastic Syndromes (MDS) – A group of disorders caused by poorly formed or dysfunctional blood cells

• Acute Myeloid Leukemia (AML) – A fast-growing cancer of the blood and bone marrow, particularly in older adults or those who cannot tolerate intensive chemotherapy

  Adverse Effects

  Common Side Effects

  • Low blood counts, leading to increased risk of infections, fatigue, or bleeding

  • Fever and flu-like symptoms

  • Nausea or vomiting

  • Injection site reactions

  • Loss of appetite

  • Headache and weakness